Study of Poziotinib in Japanese Patients With NSCLC

NCT04402008 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision, not related to safety.

Conditions

NSCLC

Interventions

DRUG: Poziotinib Once Daily Dosing
DRUG: Poziotinib Twice Daily Dosing
DRUG: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1

Sponsor

Spectrum Pharmaceuticals, Inc